New precision medicine approach could revolutionize osteoporosis care
NCT ID NCT05151484
First seen May 16, 2026 · Last updated Jun 19, 2026 · Updated 5 times
Summary
This phase 4 trial tests a personalized treatment for age-related osteoporosis using the drug teriparatide. Instead of relying on invasive bone biopsies, doctors will use blood tests to tailor the treatment to each patient's bone turnover rate. The study involves 60 participants aged 45 and older who have not taken other osteoporosis drugs. The goal is to improve bone density and reduce fracture risk without the need for surgery or biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED OSTEOPOROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Kentucky
Lexington, Kentucky, 40536, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teriparatide (a synthetic hormone given as daily injections to stimulate bone growth)
What this could lead to
If successful, this could lead to a non-invasive, personalized treatment plan for age-related osteoporosis, potentially reducing fractures and hospitalizations.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. Teriparatide can cause side effects like nausea or dizziness, and long-term safety is not fully known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.